A systematic review of intravitreal bevacizumab for the treatment of diabetic macular edema.

Authors' conclusions Although bevacizumab does not have an indication for treatment of diabetic macular edema, there is considerable interest in its use for this condition. This review found bevacizumab improved vision compared to laser therapy, insufficient evidence comparing bevacizumab to triamcinolone and lack of robust evidence for the long-term safety profile of bevacizumab. There were no trials that directly compared bevacizumab with ranibizumab for the treatment of DME, although a recently published indirect comparison suggested that they may have similar efficacy. Large, wellconducted trials are needed to provide better evidence of the effects of bevacizumab compared with other options, as well as to better define the optimal dose, timing, and duration of bevacizumab treatment in diabetic macular edema.